

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

93257

<p>Licensee</p> <p>1. Guernsey Memorial Hospital</p> <p>2. 1341 N. Clark Street Cambridge, OH 43725</p>		<p>In accordance with application dated July 24, 1992</p> <p>3. License number 34-16588-01 is amended in its entirety to read as follows:</p>	
		<p>4. Expiration date February 28, 1996</p>	
		<p>5. Docket or Reference No 030-11288</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Any byproduct material identified in 10 CFR 35.300</p> <p>D. Any byproduct material identified in 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200</p> <p>C. Any radiopharmaceutical identified in 10 CFR 35.300</p> <p>D. Prepackaged Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p> <p>D. As needed</p>	
<p>9. Authorized Use:</p> <p>A. Medical use described in 10 CFR 35.100.</p> <p>B. Medical use described in 10 CFR 35.200.</p> <p>C. Medical use described in 10 CFR 35.300</p> <p>D. In vitro studies.</p>			

CONDITIONS

10. Location of Use: 1341 N. Clark Street, Cambridge, Ohio.
11. Radiation Safety Officer: William Walker, R.T., C.N.M.T.

9302260010 920903  
PDR ADOCK 03011288  
C PDR

COPY  
2384

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number  
34-16588-01

Docket or Reference number  
030-11288

Amendment No. 12

12. Authorized Users:

- A. Jeffrey S. Moncman, M.D., for material in 10 CFR 35.100, 35.200, and 31.11.
- B. Robert E. Lawrence-Berrey, M.D., for material in 10 CFR 31.11.
- C. Arthur P. Ciacchella, M.D., for material in 10 CFR 35.100, 35.200, 35.300 and 31.11.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

14. The licensee shall maintain records of information important to safe and effective decommissioning at 1341 N. Clark Street, Cambridge, Ohio per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

15. This license is based on the licensee's statements and representations listed below:

- A. Applications dated November 19, 1990, and July 24, 1992; and
- B. Letters dated January 30, 1991, May 22, 1991 and July 24, 1992.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 03 1992

By Loren F. Hunter  
Materials Licensing Section, Region III

COPY

(FOR LFMS USE)  
INFORMATION FROM LTS

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM  
AND  
REGIONAL LICENSING SECTIONS

PROGRAM CODE: 02120  
STATUS CODE: 0  
FEE CATEGORY: 7C  
EXP. DATE: 19760228  
FEE COMMENTS:  
DECOM FIN ASSUR RECDY N  
.....

LICENSE FEE TRANSMITTAL

A. REGION III

1. APPLICATION ATTACHED  
APPLICANT/LICENSEE: GUERNSEY MEMORIAL HOSPITAL  
RECEIVED DATE: 920727  
DOCKET NO: 3011288  
CONTROL NO.: 393757  
LICENSE NO.: 34-16583-01  
ACTION TYPE: AMENDMENT

2. FEE ATTACHED  
AMOUNT: \$430.00  
CHECK NO.: 036833

3. COMMENTS

SIGNED P. DeLaff  
DATE 7-27-92

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED) ☒

1. FEE CATEGORY AND AMOUNT: 7C \$430

2. CORRECT FEE F. ID. APPLICATION MAY BE PROCESSED FOR:  
AMENDMENT ☒  
RENEWAL ☐  
LICENSE ☐

3. OTHER

SIGNED Anta Jacques  
DATE 8/12/92





# APPLICATION FOR MATERIAL LICENSE

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

APPLICATIONS FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH:

U.S. NUCLEAR REGULATORY COMMISSION  
DIVISION OF FUEL CYCLE AND MATERIAL SAFETY, NMSS  
WASHINGTON, DC 20545

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS. IF YOU ARE LOCATED IN:

CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, MAINE, MARYLAND, MASSACHUSETTS, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, PENNSYLVANIA, RHODE ISLAND, OR VERMONT, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION I  
NUCLEAR MATERIALS SAFETY SECTION B  
475 ALLENDALE ROAD  
KING OF PRUSSIA, PA 19406

ALABAMA, FLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO RICO, SOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION II  
NUCLEAR MATERIALS SAFETY SECTION  
101 MARIETTA STREET, SUITE 2900  
ATLANTA, GA 30333

IF YOU ARE LOCATED IN:

ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION III  
MATERIALS LICENSING SECTION  
799 ROOSEVELT ROAD  
GLEN ELLYH, IL 60137

ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, SOUTH DAKOTA, TEXAS, UTAH, OR WYOMING, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION IV  
MATERIAL RADIATION PROTECTION SECTION  
611 RYAN PLAZA DRIVE, SUITE 1000  
ARLINGTON, TX 76011

ALASKA, ARIZONA, CALIFORNIA, HAWAII, NEVADA, OREGON, WASHINGTON, AND U.S. TERRITORIES AND POSSESSIONS IN THE PACIFIC, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION V  
NUCLEAR MATERIALS SAFETY SECTION  
1450 MARIA LANE, SUITE 210  
WALNUT CREEK, CA 94606

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTION.

1. THIS IS AN APPLICATION FOR (Check appropriate item)

- ☐ A. NEW LICENSE  
☒ B. AMENDMENT TO LICENSE NUMBER 34-16588-01  
☐ C. RENEWAL OF LICENSE NUMBER \_\_\_\_\_

2. NAME AND MAILING ADDRESS OF APPLICANT (Include Zip Code)

Guernsey Memorial Hospital  
1341 N. Clark Street  
Cambridge OH 43725

3. ADDRESS(ES) WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED.

Same as No. 2

4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION

Daniel Patrick, NMA Medical Physics Consultation

TELEPHONE NUMBER

412-281-6113

SUBMIT ITEMS 5 THROUGH 11 ON 8 1/2 x 11" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.

5. RADIOACTIVE MATERIAL

a. Element and mass number, b. chemical and/or physical form, and c. maximum amount which will be possessed at any one time.

6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.

7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE.

8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.

9. FACILITIES AND EQUIPMENT.

10. RADIATION SAFETY PROGRAM

11. WASTE MANAGEMENT.

12. LICENSEE FEES (See 10 CFR 170 and Section 170.31)

FEE CATEGORY 7C AMOUNT ENCLOSED \$ 430.00

13. CERTIFICATION. (Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT.

THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, AND 40 AND THAT ALL INFORMATION CONTAINED HEREIN, IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.

WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948, 62 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

SIGNATURE—CERTIFYING OFFICER

TYPED/PRINTED NAME

TITLE

DATE

*Philip Hearing*

x Philip Hearing

x Senior Vice President x 7/24/92

The purpose of this amendment is to request authorization for Dr. Jeffrey S. Moncman to use Iodine-131 for hyperthyroid therapy.

RECEIVED

FOR NRC USE ONLY

TYPE OF FEE <i>Amend</i>	FEE LOG <i>Aug 2</i>	FEE CATEGORY <i>7C</i>	COMMENTS <i>Anta Jacques 8/12/99</i>	APPROVED BY <i>JUL 27 1992</i>
AMOUNT RECEIVED <i>\$430</i>	CHECK NUMBER <i>56233</i>	CONTROL NO. <i>93757</i>		REGION III

# GUERNSEY MEMORIAL HOSPITAL

Jack R. Taylor  
President  
and  
Chief Executive Officer

1341 North Clark Street  
P. O. Box 610  
Cambridge, Ohio 43725  
Phone (614) 439-3561

7/24/92

U.S.N.R.C.  
Region III  
799 Roosevelt Road  
Glen Ellyn, Illinois 60137


RE: License No. 34-16588-01

Gentlemen:

In accordance with 10CFR 35.14, let this letter serve as notification that Harry H. Tompkins, M.D. has discontinued his duties as an authorized user at this facility.

Thank you for your attention to this matter.

Sincerely,



Philip Hearing  
Senior Vice President

RECEIVED

JUL 27 1992

REGION III

JUL 27 1992

CONTROL NO.

93757

*Pm 7/24/92*

EXHIBIT 3  
SUPPLEMENT B

SUPPLEMENT		U. S. NUCLEAR REGULATORY COMMISSION	
PRECEPTOR STATEMENT			
<i>Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.</i>			
<b>1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS</b>		<b>KEY TO COLUMN C</b> <b>PERSONAL PARTICIPATION SHOULD CONSIST OF:</b>	
<b>FULL NAME</b> <div style="font-family: cursive; font-size: 1.2em;">Jeff S. Moncman MD</div>		1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.	
<b>STREET ADDRESS</b> <div style="font-family: cursive; font-size: 1.2em;">1341 Clark St.</div>		2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.	
<b>CITY</b> <div style="font-family: cursive; font-size: 1.2em;">Cambridge</div>	<b>STATE</b> <div style="font-family: cursive; font-size: 1.2em;">Ohio</div>	<b>ZIP CODE</b> <div style="font-family: cursive; font-size: 1.2em;">43725</div>	3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.
<b>2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN</b>			
ISOTOPE <small>A</small>	CONDITIONS DIAGNOSED OR TREATED <small>B</small>	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION <small>C</small>	COMMENTS <small>(Additional information or comments may be submitted in duplicate on separate sheets.) D</small>
	Thyroid scan		
	Thyroid uptake		
	Lung perfusion scan		
	Xenon ventilation study		
	Aerosol ventilation scan		
	Renal flow scan		
	Brain scan		
	Liver/spleen scan		
	Bone scan		
	Gastroesophageal study		
	LeVeen shunt study		
	Cystogram		
	Dacryocystogram		
	Cardiac perfusion scan		
	Cardiac stress ventriculogram		
	Cardiac rest ventriculogram		
	Gallium scan		

## EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER

## PRECEPTOR STATEMENT (Continued)

## 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM	5	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or I-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

## 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION

DATES

CLOCK HOURS OF EXPERIENCE

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE  
WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

Arthur Ciaccchella MD

b. NAME OF INSTITUTION

Guernsey Memorial Hospital

c. MAILING ADDRESS

1341 Clark St.


d. CITY

CAMBRIDGE

e. MATERIALS LICENSE NUMBER(S)

34-16588-01

## 5. PRECEPTOR'S SIGNATURE



7. PRECEPTOR'S NAME (Please type or print)

ARTHUR P. CIACCHELLA

8. DATE

3/20/92



SEP 15 1992

Guernsey Memorial Hospital  
ATTN: Philip Hearing  
Senior Vice President  
1341 N. Clark Street  
Cambridge, OH 43725

Dear Mr. Hearing:

Enclosed is Amendment No. 12 to your NRC License No. 34-16588-01 in accordance with your request.

Please note that we have not authorized Jeffrey S. Moncman, M.D. to use Iodine-131 for treatment of hyperthyroid which you requested. The preceptor document you submitted shows that his supervised clinical experience using Iodine-131 for treatment of hyperthyroidism includes only five treated patients. A minimum of 10 such supervised treatments is required by 10 CFR 35.930(b)(2)(i) before authorization can be granted. If Dr. Moncman can provide a preceptor statement showing the required additional experience has already been obtained or if it can be obtained and then submitted to us within the next twelve months, you may submit it as additional information to Control No. 93757 and we will continue our review of the request.

Please review the enclosed document carefully and be sure that you understand all conditions. You must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Possess radioactive material only in the quantity and form indicated in your license.
3. Use radioactive material only for the purpose(s) indicated in your license.
4. Notify NRC in writing of any change in mailing address.
5. Request and obtain appropriate amendment if you plan to change ownership of your organization, change locations of radioactive material, or make any other changes in your facility or program which are contrary to your

93757

SEP 15 1992

license conditions or representations made in your license application and any supplemental correspondence with NRC. Any amendment request should be accompanied by the appropriate fee specified in 10 CFR Part 170.

6. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.
7. Request termination of your license if you plan to permanently discontinue activities involving radioactive material prior to your expiration date.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations in your license application will result in enforcement action against you in accordance with the General Policy and Procedures for NRC Enforcement Actions, 10 CFR Part 2, Appendix C.

If you have any questions or require clarification of any of the above stated information, contact us at (708) 790-5625.

Sincerely,

Original Signed By  
Loren J. Hueter  
Materials Licensing Section

Enclosure: Amendment No. 12

R111

*LJH*  
Hueter/bt  
09/03/92